AMO 5G femtosecond laser cleared by FDA

Article

The FDA has cleared the iFS Advanced Femtosecond Laser (AMO), which is now available for order.

The FDA has cleared the iFS Advanced Femtosecond Laser (AMO), which is now available for order.

The fifth generation laser, which can cut a corneal flap within 10 seconds, includes IntraLase-Enabled Keratoplasty (IEK), and has a higher repetition rate and tighter spot separation than earlier models. It has a unique inverted bevel-in-side cut angle to improve the biomechanical stability of postoperative corneas, and can create an elliptical flap to increase the number of surgical options.

The iFS laser - part of AMO's proprietary iLASIK technology suite - has an ergonomic design, new contemporary user interface and high-resolution digital video microscope, all designed to increase surgeon comfort and ease of operating, enhancing the outcome for the patient.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.